180 related articles for article (PubMed ID: 28267056)
1. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Opin Urol; 2017 May; 27(3):225-230. PubMed ID: 28267056
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Urol Rep; 2015 Apr; 16(4):24. PubMed ID: 25764118
[TBL] [Abstract][Full Text] [Related]
3. Defining 'progression' and triggers for curative intervention during active surveillance.
Klotz L
Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance and focal therapy for low-intermediate risk prostate cancer.
Klotz L
Transl Androl Urol; 2015 Jun; 4(3):342-54. PubMed ID: 26816834
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
6. Active Surveillance for Prostate Cancer: How to Do It Right.
Garisto JD; Klotz L
Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
[TBL] [Abstract][Full Text] [Related]
7. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
12. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
13. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
Berglund RK; Masterson TA; Vora KC; Eggener SE; Eastham JA; Guillonneau BD
J Urol; 2008 Nov; 180(5):1964-7; discussion 1967-8. PubMed ID: 18801515
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
16. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
17. Active Surveillance for Intermediate Risk Prostate Cancer.
Klotz L
Curr Urol Rep; 2017 Aug; 18(10):80. PubMed ID: 28801885
[TBL] [Abstract][Full Text] [Related]
18. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
19. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer.
Goldberg H; Klaassen Z; Chandrasekar T; Fleshner N
Curr Opin Urol; 2018 Jan; 28(1):46-54. PubMed ID: 29028765
[TBL] [Abstract][Full Text] [Related]
20. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]